KX-826 for Skin Phase II Enrollment Completed: The Future of Acne Treatment

Why KX-826 Matters for Acne Care

Acne often stems from hormonal imbalances, specifically androgens like DHT that trigger sebum overproduction and clogged pores. KX-826 (pyrilutamide) is a new, topical anti-androgen that blocks androgen receptors in the skin, targeting acne at its hormonal origin, not just the surface.

From Safety to Proof: Clinical Trial Milestones

• Phase I/II (2021): The first group of patients were dosed in China. This combined trial evaluated safety, dosage tolerance, pharmacokinetics, and early efficacy for mild-to-moderate acne vulgaris.
• Phase II Enrollment Completed (Oct 2022): Kintor finished enrolling 160 acne patients across multiple regions in China. Experts used a 5-point Investigator Global Assessment (IGA) scale to define success as at least a two-grade improvement.

What This Means

There are currently no effective topical androgen antagonists approved for acne in places like China, even though the condition impacts hundreds of millions of people globally. KX-826 could meet that unmet need, especially for those with sensitive or melanin-rich skin who struggle with traditional, harsh acne treatments.

Possible Timeline & Next Steps

• Phase I/II: Established preliminary safety and dosing guidelines.
• Phase II: Now determining real-world effectiveness and tolerability.
  

An upcoming Phase III trial could confirm its potential as a groundbreaking acne treatment, providing a dermatologist-developed path to clear skin, with care and scientific integrity at the core.

Why Regenvia Cares

Regenvia believes in results that are backed by research and inclusive by default. KX-826 aligns with that mission. It's not about quick fixes, but healing acne at its hormonal root while safeguarding your skin, tone, and long-term barrier health.